Phase 1 Cardiomyopathy Trial, Recruiting NCT06327308 Sponsor: Centre Hospitalier Universitaire de Besancon Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 1 Cardiomyopathy Trial, Recruiting

NCT06327308
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have liver cirrhosis and are being considered for a liver transplant, with no medical reasons ruling out transplantation
  • Women who have gone through menopause at least 24 months ago, have had a surgical procedure that prevents pregnancy, or are using an effective form of contraception (such as the pill, contraceptive injections, an IUD, a contraceptive patch, or a double-barrier method)
  • People who have read, understood, and signed a consent form agreeing to take part in the study and follow its requirements
  • People who are covered by, or are a beneficiary of, a social security system

Who may not be able to join:

  • People under 18 years old or over 70 years old
  • People who have already received a liver transplant
  • People who have a TIPS (a shunt placed in the liver to manage blood pressure — confirm with trial site if unsure)
  • People with known heart conditions, including high blood pressure in the lungs related to liver disease, history of coronary artery disease with heart muscle damage, or a history of heart muscle disease or inflammation
  • People with uncontrolled high blood pressure and a thickened heart wall (a specific measurement of ≥15mm — confirm with trial site)
  • People who are in a state of haemodynamic instability (meaning the body is struggling to maintain stable blood circulation — confirm with trial site)
  • People with Type 1 diabetes
  • People with an active bacterial infection at the time of the trial
  • People with HIV infection, or whose HIV status is unknown
  • People who cannot have an MRI scan, including those with pacemakers, implanted defibrillators, certain metal implants or clips, insulin pumps, certain types of heart valves, eye or ear implants, metal fragments in the eyes, severe kidney problems, inability to hold their breath briefly, claustrophobia, or a known contraindication to contrast dye used in imaging
  • People with severe brain complications from liver disease (hepatic encephalopathy) who are unable to understand information and do not have a trusted representative to assist them
  • People under legal guardianship or who have limited legal capacity
  • People who are currently detained or deprived of their liberty
  • Women who are pregnant or breastfeeding
  • People the trial investigators believe are unlikely to cooperate with the study requirements
  • People currently enrolled in another clinical trial or listed in a national register that prevents participation in additional studies

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Thierry THEVENOT, MD, PHD, Centre Hospitalier Universitaire de Besancon

Phone: +33381669457

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Centre Hospitalier Universitaire de Besancon
Registry
ClinicalTrials.gov
Start date
11 March 2025
Est. completion
11 March 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Primary outcome measure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov